Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Mallinckrodt
Merck
Baxter
Moodys

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,910,131

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,910,131
Title:Method of treating seizures using modified release formulations of oxcarbazepine
Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Inventor(s): Bhatt; Padmanabh P. (Rockville, MD), Kidane; Argaw (Montgomery Village, MD), Edwards; Kevin (Lovettsville, VA)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:12/230,276
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,910,131
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form; Composition;

Drugs Protected by US Patent 7,910,131

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No   Start Trial   Start Trial TREATMENT OF PARTIAL-ONSET SEIZURES   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-002 Oct 19, 2012 RX Yes No   Start Trial   Start Trial TREATMENT OF PARTIAL-ONSET SEIZURES   Start Trial
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes   Start Trial   Start Trial TREATMENT OF PARTIAL-ONSET SEIZURES   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,910,131

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 496623   Start Trial
Australia 2007242984   Start Trial
Canada 2597740   Start Trial
China 101489560   Start Trial
Germany 602007012236   Start Trial
European Patent Office 2026815   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Express Scripts
McKinsey
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.